医学
嵌合抗原受体
淋巴瘤
抗原
T细胞
基因工程
免疫学
癌症研究
细胞
免疫系统
基因
遗传学
生物化学
生物
作者
Jennifer N. Brudno,Marcela V. Maus,Christian S. Hinrichs
出处
期刊:JAMA
[American Medical Association]
日期:2024-11-04
卷期号:332 (22): 1924-1924
被引量:236
标识
DOI:10.1001/jama.2024.19462
摘要
CAR T-cell therapy is an FDA-approved therapy that has improved progression-free survival for multiple myeloma, improved overall survival for large B-cell lymphoma, and attained high rates of cancer remission for other hematologic malignancies such as acute lymphoblastic leukemia, follicular lymphoma, and mantle cell lymphoma. Recently approved T lymphocyte-based therapies demonstrated the potential for improved outcomes in solid tumor malignancies.
科研通智能强力驱动
Strongly Powered by AbleSci AI